• SELECT SITE CURRENCY
Select a currency for use throughout the site
Innovative Partnering and Dealmaking Strategies
Decision Resources, Inc, November 2011
Pharmaceutical companies are exploring numerous creative strategies to improve the outcomes of partnerships and collaborations. In an environment of increasing budget restraints and intense competition, these companies are increasingly focusing on return on investment, patient needs, and reimbursement issues in collaborative arrangements. The goal is to bring innovative and lucrative drug candidates through the development pipeline and to market them more efficiently.
Questions answered in this report:
- Pharmaceutical companies are emphasizing business development activities to fill weakened pipelines. What types of deals are of interest to pharmaceutical companies? How are the dealmaking strategies of Big Pharma evolving?
- Pharmaceutical companies are becoming more open to pooling development resources. How are major pharmaceutical companies willing to collaborate with each other on early-stage programs? Which companies are pioneering new forms of early-stage pharma/pharma partnerships? How can pharma/pharma collaborations create market opportunities?
- A dearth of funding for young biotech companies is encouraging the creation of novel business models. What novel business structures have been developed to help biotech companies deliver high-value assets to Big Pharma? Which companies have been successful in implementing these structures?
- Pharma/academic collaborations are on the rise. What novel approaches are pharmaceutical companies using to collaborate with academic institutions? Which companies are pursuing these approaches?
- In dealmaking, drug developers are paying increasing attention to reimbursement, market access, and patient needs. What factors are influencing Big Pharma’s response to reimbursement and market access issues? What novel partnerships have companies formed to address these issues? How are companies seeking to better address unmet patient needs?
- Pooling resources: Cancer, hepatitis C, pharma/pharma collaborations, early-stage development programs, evolving treatment paradigms, creating market opportunities.
- Evolving pharma/biotech strategies: Mitigating risk, investment incentives, forecast for late-stage development pipelines, R&D funding gap, novel consortium strategies, company spin-offs.
- Academic partnership strategies: Externalization, open innovation, pharmaceutical R&D centers, partnerships.
- Payers, market access, and personalized medicine: Factors influencing focus on payers and reimbursement in dealmaking, partnerships with third-party payers, leveraging patient data and information technology, personalized medicine, translational medicine.
- Generating value from frozen assets: Novel outlicensing efforts, repositioning stagnant assets.
- Outlook: Leading industry executive viewpoints, evolving strategies.
Pooling Resources More Effectively
Combining to Conquer in Cancer
AstraZeneca and Merck
Sanofi and Merck KGaA
An Evolving Treatment Paradigm in Hepatitis C
Creating Market Opportunities in Asia: Lung and Gastric Cancer
Evolving Pharma/Biotech Strategies: Mitigating Risk to Incentivize Investment
Pfizer and Ablexis
Amunix: Versartis and Diartis
New Strategies in Academia: Externalization and Open Innovation
Pfizer’s Centers for Therapeutic Innovation
Payers, Market Access, and Personalized Medicine
Collaborating with Payers to Increase Market Access
Merck and Cigna
Novartis and NICE
Leveraging Patient Data and Information Technology: The Path to Personalized Medicine
Sanofi and Medco
Generating Value from Frozen Assets
Outlook for Novel Partnering and Business Strategies
About the Author
- Advent Venture Partners
- Biogen Idec
- Eli Lilly
- Index Ventures
- Merck KGaA
- Merck Serono
- New Leaf Venture Partners
- Vertex Pharmaceuticals